• Follow Us
CDI Labs LogoCDI Labs Company Logo
  • LAB SERVICES
      • Service Platforms
      • OVERVIEW
      • HuProt™ Services
      • VirD™ Services
      • VirScan® Services*
      • HuScan® Services*
      • MouseScan™ Services*
      • Tech Access ProgramCustom PhIP-Seq Libraries*
      • Autoantibody Seromics Services
      • OVERVIEW
      • Biomarker Discovery
      • Patient Stratification
      • Patient Response / Adverse Reaction Prediction
      • Diagnostic Development
      • Vaccine Development and Safety
      • Viral Exposure Profiling
      • Target ID Services
      • OVERVIEW
      • Protein-Protein Interactions
      • Protein-Nucleic Acid Interactions
      • Target Deconvolution / Target Discovery
      • Antibody Specificity Validation
      • Post-translational Modification Specificity Testing
      • Chemically Induced Proximity (CIP)
      • Disease Areas
      • OVERVIEW
      • Autoimmune Disease
      • Oncology
      • Neurological Disease
      • Infectious Disease
      • Genetic Disease
      • * Provided exclusively by CDI Labs Canada.
  • SPECIALIZED CRO SERVICES
      • Specialized CRO Services
      • OVERVIEW
      • Antibody Development
      • Antibody Pairs
      • Protein Production
      • Cell Therapy Immunogenicity Testing
      • CRISPR-Cas9 Immunogenicity Testing
      • Post-translational Modification Specificity Profiling
      • Diagnostic Development
  • PROTEOMICS TECHNOLOGIES
      • HuProt™ MicroarrayContains 21,000+ Full-length Human Proteins
      • VirD™ Membrane ProteinContains429 Membrane Proteins and Isoforms
      • VirScan® PhIP-Seq*Detect antibodies against 68,000+ Viral Protein Sequences
      • HuScan® PhIP-Seq*Detect antibodies against 48,921 Human Proteins and Isoforms
      • MouseScan™ PhIP-Seq* Detect antibodies against 50,135 Murine Proteins and Isoforms
      • * Provided exclusively by CDI Labs Canada.
  • BIOINFORMATICS
      • Bioinformatics
      • OVERVIEW
  • RESOURCES
      • Resources
      • Library Content
      • Publications
      • Videos and Webinars
      • FAQs
  • NEWS  &  EVENTS
      • Blogs
      • Events
      • News
  • COMPANY
      • About Us
      • Leadership
      • Meet CDI Labs
      • Tech Access ProgramCustom PhIP-Seq Libraries*
      • Customer Testimonials
      • Contact Us
      • Sign-up for Our eNews
      • Privacy Policy
  • CONTACT US

You are now leaving the CDI Labs U.S. website and will be directed to the CDI Labs Canada website.

< Older Newer >
Download PDF
  • Share

Wednesday, Mar 28 2018

CDI Labs' Monoclonal Antibody Development Pipeline featured in Nature Methods

Proteomics company leverages microarray capability to develop truly monospecific monoclonal antibodies

MAYAGUEZ, Puerto Rico and BALTIMORE, March 28, 2018 - A newly published article in Nature Methods describes CDI Laboratories' participation in the NIH Protein Capture Reagents Program (PCRP). CDI's patented method of antibody development (FastMAb®) features the use of CDI's HuProt™ microarray (containing 81% of the human proteome) to ensure that the antibodies produced are truly mono-specific.


The paper gives a detailed description of the collaborative effort between CDI Laboratories and the Labs of Dr. Seth Blackshaw, Dr. Heng Zhu and Dr. Jef Boeke, as well as many others (see http://rdcu.be/JnJI ).


A number of recent articles and commentaries published in high impact journals detail the problems with antibody cross-reactivity, which impacts data relevancy and results in a significant amount of time and money wasted on poor antibodies. In addition, there is growing demand from the NIH regarding the need for antibody standardization, to ensure that reagents used in publications are actually detecting their intended targets. Antibodies are among the most commonly employed biological research reagents, valued as tools used primarily to identify and/or isolate molecules of interest. It is also becoming clear that they are the cause of many problems regarding data interpretation, and may hinder researchers' abilities to reach unambiguous conclusions (Baker M. (2015) Reproducibility crisis: Blame it on the Antibodies. Nature 521: 274-276).  CDI's patented method helps to alleviate this reproducibility problem by producing antibodies that are truly specific to its intended target. By first testing the candidate antibodies against most of the human proteome, only antibodies proven to be specific are then released through CDI's pipeline. 


"CDI is very proud of its collaboration between all the great labs featured in this current Nature Methods paper," said Scott Paschke, CDI Vice President. "The fact that many antibodies used in life science research are less than monospecific is a huge problem. CDI has developed a very robust monoclonal antibody pipeline, using its protein microarray expertise, to help alleviate the problem of non-specific antibody binding."



About CDI - A privately-owned biotechnology corporation, CDI Labs focuses on protein/antibody microarray design, production, and custom assay services. CDI's flagship - HuProt™ - is the most comprehensive human proteome microarray in the industry, allowing thousands of protein interactions to be profiled in parallel. HuProt™ enables R&D of future therapeutic and diagnostic tools to proceed more rapidly and cost-effectively. The HuProt™ arrays are available for purchase by labs with in-house microarray scanning capability. Alternatively, CDI's Discovery Services division offers contract assay design, research, bioinformatics and custom-configured microarray production on a per-project basis. CDI's FastMAb® hybridoma development service addresses the urgent need for monoclonal antibodies with unprecedented specificity, for detecting research, diagnostic or therapeutic targets. FastMAb® antibodies are evaluated for specificity on HuProt™ arrays. The Company exports products worldwide and is actively expanding its clientele base and academic and industrial collaborations.


For more information, visit cdi-lab.com




Media Contact:

Scott Paschke, Vice President

CDI Laboratories Inc

518-534-2881 (direct)

[email protected]

  • CDI LABSLinkedin Feed
CDI Labs Footer LogoCDI Labs Company Footer Logo

Become part of the CDI Labs community

Sign up to receive emails on our latest news and updates.

Your First Name
Your Last Name
Your Work Email

Please enter ONLY your work email address.

Sign Up Submit Button

PLATFORMS

  • HuProt™ Proteome Microarray
  • VirD™ Membrane Protein Array
  • VirScan® Viral PhIP-Seq*
  • HuScan® Human PhIP-Seq*
  • MouseScan™ Murine PhIP-Seq*
  • * Provided exclusively by CDI Labs Canada.

SERVICES

  • HuProt™ Services
  • VirD™ Services
  • VirScan® Services*
  • HuScan® Services*
  • MouseScan™ Services*
  • Antibody Development
  • Autoantibody Seromics Overview
  • Target ID Overview
  • Disease Areas Overview
  • Specialized CRO Overview
  • Bioinformatics Overview
  • * Provided exclusively by CDI Labs Canada.

COMPANY

  • Resources
  • Library Content
  • Publications
  • FAQs
  • Videos and Webinars
  • Blogs
  • Events
  • News
  • Sign-up for Our eNews
  • About Us
  • Leadership

CONTACT

  • Email: [email protected]
  • Tel: +1 844-539-6296
  • CONTACT US
  • General Inquiries
  • [email protected]
  • Tel: +1 510 858-2855
  • Technical Support
  • [email protected]
  • Tel: +1 844 539-6296
  • Mailing Address
  • PO. Box 569
  • Mayagüez. PR 00681-0569
  • USA
  • CDI Labs - Mayagüez
  • 12 W Mendez Vigo Avenue
  • 2nd Floor
  • Mayagüez, PR 00680
  • USA
  • Tel: +1 939-280-5293
  • DIRECTIONS
  • CDI Labs - Baltimore
  • 1 N. Haven Street
  • Suite B001
  • Baltimore, MD 21224
  • USA
  • Tel: +1 844-539-6296
  • DIRECTIONS
  • CDI Labs Canada - Toronto
  • MaRS Centre - West Tower
  • 661 University Ave
  • Suite 1300
  • Toronto, ON
  • CANADA M5G 0B7
  • Tel: +1 647-243-5289
  • DIRECTIONS
  • Follow Us

FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.

© 2025 CDI Labs. All rights reserved.

  • Privacy Policy
  • |
  • Cookie Policy
  • |
  • Terms of Use - Web
  • |
  • Terms & Conditions - Sales
  • |
  • Terms & Conditions - Services